Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.

Détails

Ressource 1Télécharger: 18616418_Postprint.pdf (1175.80 [Ko])
Etat: Public
Version: de l'auteur⸱e
ID Serval
serval:BIB_365F37D27EAF
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.
Périodique
Expert Opinion on Investigational Drugs
Auteur⸱e⸱s
Reardon D.A., Nabors L.B., Stupp R., Mikkelsen T.
ISSN
1744-7658
Statut éditorial
Publié
Date de publication
2008
Peer-reviewed
Oui
Volume
17
Numéro
8
Pages
1225-1235
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Review
Résumé
BACKGROUND: Glioblastoma multiforme (GBM), a highly invasive and vascular cancer, responds poorly to conventional cytotoxic therapy. Integrins, widely expressed in GBM and tumor vasculature, mediate cell survival, migration and angiogenesis. Cilengitide is a potent alphavbeta3 and alphavbeta5 integrin inhibitor. OBJECTIVE: To summarize the preclinical and clinical experience with cilengitide for GBM. METHODS: Preclinical studies and clinical trials evaluating cilengitide for GBM were reviewed. RESULTS/CONCLUSIONS: Cilengitide is active and synergizes with external beam radiotherapy in preclinical GBM models. In clinical trials for recurrent GBM, single-agent cilengitide has antitumor benefits and minimal toxicity. Among newly diagnosed GBM patients, single-arm studies incorporating cilengitide into standard external beam radiotherapy/temozolomide have shown encouraging activity with no increased toxicity and have led to a planned randomized Phase III trial.
Mots-clé
Animals, Antineoplastic Agents, Central Nervous System Neoplasms, Clinical Trials as Topic, Drug Evaluation, Preclinical, Glioblastoma, Humans, Integrins, Models, Molecular, Oligopeptides, Protein Binding, Snake Venoms, Treatment Outcome
Pubmed
Web of science
Création de la notice
12/03/2009 13:27
Dernière modification de la notice
20/08/2019 13:24
Données d'usage